利塞膦酸钠胶囊治疗绝经后骨质疏松症疗效的影响因素分析

目的：分析利塞膦酸钠胶囊治疗绝经后骨质疏松症（PMOP）疗效的影响因素。方法：将35例入选患者随机分入观察组和对照组，观察组晨起口服利塞膦酸钠胶囊，对照组口服安慰剂，全部患者均在晚间口服凯思立D片，疗程为12个月。用多元线性回归分析年龄、身高、体重、BMI、绝经年数、治疗方法等因素对疗效的影响。结果：影响因素中只有“组别”一项进入回归方程（P〈0．05）。结论：利塞膦酸钠胶囊是使PMOP患者腰椎骨密度增加的独立影响因子，年增加骨密度约0．041g／cm^2。

Analysis on influencing factor of effect for treating postmenopausal osteoporosis with risedronate sodium capsules

To analyze the influencing factor of effect for treating postmenopausal osteoporosis with risedronate sodium capsules. METHODS: This is a randomized double-blind placebo-controlled clinical re-search . All patients were divided into two groups, trail group and control group. During 12 months, patients of trail group took risedronate sodium capsules orally every morning, patients of control group took placebo orally every morning, and at the same time all patients took calcichew D orally every night. Multiple linear regres-sion analysis on influencing factor of effect including person's age, height, body weight, body mass index,menopause years, and therapeutic method. RE-SULTS: The therapeutic method was eventually con-ducted into the regression equation(P < 0.05) . CON-CLUSION: Risedronate sodium capsule is the inde-pendent influencing factor for increasing bone mineral density(BMD), and the BMD has annual gain 0.041 g/cm~2.